vol VIII no2, 15 april 2002
STEROID RESISTANT ASTHMA
Chronic asthma is an eminently steroid responsive disease. When patients show no response to steroids or require high doses of steroids for asthma control, they require a detailed evaluation of many conditions which includes steroid resistant asthma.
Steroid resistant
asthma is a diagnosis of exclusion. If true steroid resistance is proven,
steroids have to be stopped and alternative anti inflammatory therapy be
instituted.
Causes of poor response to steroids are:
1. Wrong diagnosis of asthma or associated/ complicating conditions with asthma such as Allergic bronchopulmonary aspergillosis (ABPA), gastroesophageal reflux disease (GERD), postnasal drip and obstructive sleep apnoea (OSA).
2.
Insufficient dose of steroids
reaching airways.
3.
Continuing exposure to
sensitizing agents.
4.
Asthma inducing drugs like
beta blockers or asprin.
5.
Excessive use of beta- 2
agonists.
Definition of steroid resistant asthma
Those patients with baseline, morning pre- bronchodilator
FEV1 < 70-80% of predicted who improve significantly with beta
agonists but by < 15% after 40 mg prednisolone for 14 days are defined as
having steroid resistant asthma.
Types of steroid resistant asthma
TYPE I
RESISTANCE: is a relative steroid
resistance characterized by an increased Kd (dissociation constant) of the
steroid receptors, leading to a decreased affinity of the receptors to steroid.
This reduced affinity is limited to T- cells and as non T- cells have a normal
affinity, these patients are prone to side effects of the steroids. Patients
with Type I resistance become sensitive to steroids after a brief period of
withdrawl of steroids or if higher doses of steroids are used.
TYPE
II RESISTANCE: this is a
complete steroid resistance which is analogous to primary cortisol resistance.
These patients have a reduced number of steroid receptors. These patients donot
respond to even large doses of steroid and do not experience steroid side
effects.
Approach to steroid resistant asthma
1. Rule out alternative diagnoses or
associated illnesses
|
Adults |
|
Vocal
cord dysfunction Hyperventilation syndrome |
|
Allergic
bronchopulmonary Endobronchial
obstruction |
|
aspergillosis
(ABPA) Factitious
asthma |
|
COPD Gastroesophageal
reflux |
|
Postnasal
drip disease
(GERD) |
|
Obstructive
sleep apnea |
|
Children |
|
Foreign
body aspiration Tracheobronchomegaly |
|
Cystic
fibrosis Alpha
1 antitrypsin deficiency |
|
Bronchiolitis
obliterans Vocal
cord dysfunction |
2.
Assure that adequate doses
of steroids reach the airway
v Optimize the dose of steroids
v Proper technique of inhaler use should be reinforced
v Ensure good compliance to treatment
in case of oral steroids, rule out poor gastrointestinal
absorption (concomitant antacid, cholestyramine, charcoal therapy) and rapid
eleminination (concomitant anticonvulsant therapy)
Treat local side effects of steroids
v Terminate the exposure to
allergens at home in the work place. Rule out the aggravating factors such as
GERD, OSA, rhinitis, drug intake (aspirin, beta blockers, excessive beta
agonist use)
v Ensure a strict management
plan for six months with objective methods of control such as spirometry on
office visits and routine peak flow monitoring.
v Maximise anti - inflammatory and reserve bronchodilator therapy for
rescue treatment and nocturnal exacerbations, consider use of long acting beta
agonists and theophylline in accordance with chrono pharmacological principles.
v If patient is on oral glucocorticosteroids, consider a split-dosing
regime with the second dose administered in the afternoon.
With above all measures, if the patients fail to
improve or maintain improvement, a diagnosis of steroid resistant asthma should
be seriously considered and glucocortico pharmokinetics and glucocortico
receptors should be evaluated.
|
|
|
Alternative therapies in steroid
resistant asthma |
|
v Methotrexate @ 10-15 mg/week *
Gold salts |
|
v Intravenous immunoglobulin given *
Troleandomycin |
|
once a month
for 6 months *
Cyclosporine @ 3-5 |
|
m g/kg/day |
|
Future theraputic strategies for SRA |
|
v
Anti adhesion molecules *
Potassium channel openers |
|
v
Anti cytokine agents *
Newer steroids with better binding properties |
|
v
VIP analogs |
|
v
Nitrodilators |
|
v
Selective PDE4 inhibitors |
Dr. Uma MaheshwariMD (Med.). DM (Pulm & Critical Care Med)
Senior Resident, PGIMER, Chandigarh
RESPIRATORY DISEASE IN PREGNANCY (III)
Acute Respiratory Distress in Pregnancy
The reduced functional residual capacity and increased
oxygen consumption found in normal pregnancy increases the risk of hypoxemia
during intubation and in the event of apnea.
v Fetal viability depends on adequate oxygen delivery. As a result of
dilutional anemia of pregnancy, cardiac output becomes the critical determinant
of fetal oxygen delivery and must be maintained.
v Vasoactive drugs should be used with caution in pregnancy patient,
since they may reduce uterine blood flow.
v In ARDS, permissive hypercapnia is not an attractive option since
fetal acidosis limits the ability to bind oxygen to fetal hemoglobin.
v Cardiopulmonary resuscitation must be modified in pregnancy : it
includes emergency cesarean section in selected patients. Delivery with in 4 to
5 minutes of the arrest will improve the chance of a good outcome for both the
mother and the fetus.
|
Differential
diagnosis of Acute Respiratory Distress in Pregnancy. |
|||
|
|||
|
Venous thromboembolism Evidence of deep venous Normal / atelectasis / |
|||
|
Thrombosis,
pleuritic chest pain, effusion |
|||
|
positive V/Q
scan, leg dopplers |
|||
|
angiogram |
|||
|
Amniotic fluid embolism Hemodynamic collapse, Normal / pulmonary |
|||
|
seizures,
disseminated edema |
|||
|
intravascular
coagulation (DIC) |
|||
|
Pulmonary edema secondary Hypertension, proteinuria Pulmonary edema |
|||
|
To preeclampsia |
|||
|
Tocolytic Pulmonary edema Tocolytic administration, Pulmonary edema |
|||
|
rapid
improvement |
|||
|
Aspiration pneumonitis Vomitting, reflux, fever Focal infiltrate/ |
|||
|
Pulmonary edema |
|||
|
Peripartum cardiomyopathy Gradual onset, cardiac gallop Cardiomegaly, |
|||
|
Pulmonary edema |
|||
|
Pneumomediastinum Occurs during delivery, Pneumomediastinum, |
|||
|
subcutaneous emphysema subcutaneous air |
|||
|
Air embolism Profound hypotension,
cardic Normal /
pulmonary |
|||
|
murmur edema |
|||
|
Others : asthma, pneumonia As for nonpregnant patint As for nonpragnant |
|||
|
Cardiac disease,ARDS
patient |
Amniotic
Fluid Embolism
v Causes 11-13% of all
maternal deaths with mortality of 86%
v Most important risk factor
for amniotic fluid embolism are maternal age and multiparity. Other less
important risk factors include lower segment cesarean section, intrauterine
manipulation, pregnancy with intrauterine growth retardation. The classic presentation
is the abrupt onset of severe dyspnea, tachypnea, and cyanosis during labour or
soon after delivery associated with cardiovascular collapse, hypoxemia and
seizures. Shock and bledding can be the intial presentation.
v Pathophysiology : The cellular and other debris present in the
fluid embolism may cause mechanical obstruction of pulmonary vasculature. It
can also cause maternal systemic reaction, cytokine release and ARDS. Elevation
of PCWP, and depressed left ventricular performance have also been observed in
some patients.
v Pulmonary microvascular cytology analysis can be useful in making a
diagnosis of amniotic fluid embolism. It is obtained by withdrawing blood from
the distal lumen of pulmonary artery catheter after wedging. In patients with
amniotic fluid embolism, there will be large numbers of fetal squames, mucin,
hair which are coated with neutrophilis.
v Treatment is supportive and is aimed at ensuring adequate
oxygenation and stablizing the circulation. Factor replacement therapy may
become necessary for bleeding due to DIC. Intravenous corticosteroids has been
reported to be of benefit in limited case reports.
Tocolytic- induced pulmonary edema
v Most common cause of pulmonary edema in pregnancy.
v Associated with beta - adrenergic agonist use (ritodine,
terbutaline, isoxuprine, salbutamol) which are used to inhibit preterm
labour.It is never seen when these agents are used for treatment of asthma.
v Pathogenesis : pulmonary capillary leak is suggested as the cause
since PCWP is normal in most patients. Fluid overload has also been speculated
as the cause of pulmonary oedema.
v Dyspnea, tachypnea, and crackles are typical and they occur during
or less than 24 hrs. afters tocolytic agents are stopped.
v Responds promptly to oxygen and diuretics.
Dr. Balamugesh T., M.D.
Senior Resident
Department of Pulmonary Medicine
PGIMER, Chandigarh.
During the last 4 decades lung function tests have evolved
from tools for physiologic studies to clinical tools for case management,
routine health examination and public health screening. These tests are
interpreted in relation to reference values and in terms of whether or not they
are within the normal range.
Sources and variation in lung function
Like all clinical measurements, lung function tests are
subjected to variations due to technical and biologic factors, disease or
dysfunction.
In clinical pulmonary function testing. It is important to
minimize the variation caused by
disease can be properly interpreted.
The American Thoracic Society recommends that :
1.
Laboratory directors should be
constantly on guard to maintain the precision and accuracy of the measurements
made in the laboratories and should be aware of the potential sources of
technical variation.
2.
The spirometer should be kept
between 17- 40 degree celsius to minimize temperature related errors.
3.
Computer calculations should
be validated.
Statistical considerations
Reference equations provide a context for evaluating the
pulmonary function values of an individual patient or subject in comparison to
the distribution of measurements in a reference population. Regression
equations are economical and efficient method to describe expected values as a
function of sex, height and age. Linear regression is the most common model
used to describe pulmonary function data in adults. Complex equations provide
more plausible models and reduce the average differences between observed and
predicted values in comparison with simple linear equations at the cost of
increased complexity of computations.
Distributions of FEV1 and FVC in population
studies are close to gaussian curve in the middle age range, but not at
extremes. Distributions of the flow measurements and the ratios measures are
not symmetric. A lower limit can be estimated from a regression model. For
spirometry values less than 5th percentile are taken as below in the
expected range.
Selecting reference values
The choice of reference values should be matter of careful
consideration of laboratory directors and should not be left to the judgement
of manufactures of automated equipment. The source of the reference values
shuld be indicated on the reports. The following must be kept in mind :
i.
Epidemiological
considerations
The reference values should not come from studies based on hospital
patients. It should be based on cross- sectional studies and the subjects
should be free of respiratory symptoms and disease. The reference values for
both males and females must be chosen from the same population- source and
there should be based on nonsmokers. Altitude is also important in selection of
reference values for flow rates and DLCO.
ii Statistical considerations
The prediction equation for adults should include age
and height as independent variables. Separate equations are mandatory for men
and women. Linear equations perform adequately for adults though they may
overpredict in young adults and underpredict in the elderely. Reference
equations should not be extrapolated for ages and heights beyond those covered
by the data that generated them.
Lower limits of normal (LLN)
The normal ranges should be based on
calculated fifth percentiles. The LLN are variable and patient values that lie
close to the lower ;limits should be interpreted with caution. The use of 80%
of the predicted for LLN for adult pulmonary function test parameters is not
recommended. It may be acceptable in children. In adults, it is not acceptable
to use a fixed FEV1/ FVC ratio as LLN.
Dr. Vinod Chandran, MD (Medicine)
Senior
Resident, Internal Medicine